70 results about "Subarachnoid hemorrhage" patented technology

It is intended to provide a drug for improving prognosis for subarachnoid hemorrhage which contains, as the active ingredient, at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof, and a method of improving prognosis for subarachnoid hemorrhage which comprises orally or gastrically administering the above drug.

Methods and apparatus for treating hydrocephalus caused by obstructions in the ventricular system and subarachnoid space of the brain. Embodiments include medical devices and methods for use within the subarachnoid space of the central nervous system to gain access to and treat an obstruction within the ventricles of the brain or a subarachnoid hemorrhage. The obstruction may be aspirated by an aspiration catheter for use in the subarachnoid space. A subarachnoid delivery catheter may then be used to deliver an intraventricular shunt to the opening in the obstruction via the subarachnoid space. A distal end of the delivery catheter is navigated across the obstruction to deploy the intraventricular shunt therein. The intraventricular shunt so positioned reopens the pathway between the ventricles and permits the return of normal cerebrospinal fluid flow there through.

The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia. The invention also relates to treatment of patients suffering from acute ischemic stroke, acute hemorrhagic stroke, subarachnoid hemorrhage, cerebral venous thrombosis or global cerebral ischemia associated with cardiac arrest. Further, the invention provides compositions of contrast media or similar exogenous media, which are intended for use in diagnostic or therapeutic applications for introduction into the intravascular, intrathecal or the intracranial space, comprising a mast cell degranulation-blocking and/or mast cell activation-blocking agent.

The invention relates to a method for refining a sulfonyl isoquinoline derivative generally known as a Fasudil hydrochloride medicament for treating cerebral spasm caused by subarachnoid hemorrhage. The method of the invention comprises the steps of purification and refining and salification, wherein the step of purification comprises washing with water, concentrating, acidifying, extracting and crystallizing; and the step of salification and refining combines the Fasudil salification and subsequent refining of the prior art. The purification, refining and salification method of the inventionhas the advantages of simplifying operation flow, shortening production period, reducing production cost, improving product quality and bringing a great convenience to industrial production.

The invention discloses application of sorafenib shown in a formula (I) in the preparation of a medicinal composition for treating early brain injury (EBI) after subarachnoid hemorrhage (SAH). Due to the adoption of the sorafenib, the activation of Raf-1/ERK1/2 and Raf-1/NF-kappa B signal paths can be restrained, hydrocephalus degrees, the permeability increase degrees of a blood brain barrier and cell apoptosis degrees can be reduced, a certain treatment effect can be displayed, and a new path can be provided for preventing and treating the EBI after the SAH.

Described herein are methods of treating ischemic injury comprising administering to a subject in need thereof a therapeutically effective amount of a substituted porphyrin compound. Also disclosed are methods of providing neuroprotection, methods of treating subarachnoid hemorrhage, methods of treating traumatic brain injury and methods of treating spinal cord injury using substituted porphyrins.

The invention discloses an application of oldenlandia diffusa, which means that oldenlandia diffusa is used as a medicine for treating subarachnoid hemorrhage. According to the invention, animal model experiments verify that oldenlandia diffusa can alleviate the degree of encephaledema caused by subarachnoid hemorrhage, promote absorption of aneurysmal subarachnoid residual blood, reduce the degree of damage of the blood brain barrier, alleviate the degree of spasm of the base artery blood vessel of the brain and improve the neurological score and the like. By improving the several clinical indexes to further protect the brain tissues, the oldenlandia diffusa has a remarkable treatment effect on subarachnoid hemorrhage.

The invention belongs to the field of drug preparation, and particularly relates to antisense oligonucleotide for miR-103-3p. The nucleotide sequence of the antisense oligonucleotide for the miR-103-3p is shown as SEQ ID NO.1. The antisense oligonucleotide for the miR-103-3p can be used for preparing a drug for treating subarachnoid hemorrhage, is low in toxicity and can relieve early brain injuries occurring after subarachnoid hemorrhage.

The invention provides an application of extracellular vesicles derived from mesenchymal stem cells in treatment of subarachnoid hemorrhage, which belongs to the technical field of molecular biology.The MSCs extracellular vesicles (MSCs-EVs) have the effects of relieving SAH complications, and improving prognosis and the like. Specifically, the MSCs-EVs can effectively improve the neuroinflammation reaction after subarachnoid hemorrhage (SAH), promote the phenotypic transformation of microglial cells to M2, and relieve the symptoms of neurological impairment, cerebral water content increase and the like caused by subarachnoid hemorrhage.

The invention discloses application of dimethyl fumarate to preparation of medicine for treating early brain injury (EBI) after subarachnoid hemorrhage (SAH). The dimethyl fumarate can activate a Keap1-Nrf2-ARE signal pathway, so that the EBI after SAH is reduced, and EBI development is weakened, in addition, the situations of cortex cell apoptosis, nervous necrosis, encephaledema, and blood-brain barrier damage are improved, and a novel method for clinically treating the EBI after the SAH is provided.

The invention provides a biomarker of subarachnoid hemorrhage indicating poor prognosis. The poor prognosis is delayed cerebral infarction, and the marker consists of the following miRNAs: miR-4463, miR-4532 and miR-1290, and may also comprises miR-4793. The invention also provides a method for diagnosing subarachnoid hemorrhage or prognosis thereof by using the biomarker. The invention also provides a kit and a chip containing the biomarker for diagnosing subarachnoid hemorrhage or prognosis thereof, and a preparation method thereof.

The invention provides the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, and belongs to the technical field of biomedicine and molecular biology. According to the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, the potential therapeutic effects of mesenchymal stem cell exosomes in SAH are explored, particularly in the effect on cognitive function. It is proved that the mesenchymal stem cell exosomes can reduce early brain damage after SAH and improve the cognitive function. In the mechanism, it is demonstrated by the exosomesrich in miR-21 play an important role in mediating effect on inhibiting neuronal apoptosis. According to the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, it is actually proved that miR-21 in the mesenchymal stem cell exosomes reduces brain damage after SAH by inhibiting the neuronal apoptosis, the neural behavior is improved through a PTEN/Akt pathway, potentialnovel restorative treatment methods and strategies are provided for SAH patients with the risk of cognitive deficits, and thus the good practical application value is obtained.

The invention relates to a method for making a novel subarachnoid hemorrhage model, and belongs to the technical field of biological experiment supplies. The technical solution of the present invention is: a method for making a novel subarachnoid hemorrhage model, comprising the following steps: selection of biological models, preparation of biological models, insertion of detection probes, model making, postoperative care of biological models, and optimization of biological models. The manufacturing method of model technology has the advantages of shortening the modeling time, accurate modeling simulation and improving the efficiency of modeling.

The invention relates to a neuroprotective composition derived from mesenchymal stem cells, especially a neuroprotective composition derived from the primary culture of dental pulp mesenchymal stem cells. The invention also relates to processes of preparing the neuroprotective composition, and medical uses of the neuroprotective composition in the treatment of neurological diseases associated withneuronal damage, including subarachnoid haemorrhage and Parkinson's disease.

The invention provides an application of strictosamide in preparing medicaments for treating subarachnoid hemorrhage, which solves the problem that the medicaments for conventional treatment of subarachnoid hemorrhage are in shortage. The strictosamide has the following advantages and positive effects: strictosamide can markedly reduce the degree of encephaledema caused by subarachnoid hemorrhage, reduce the amount of residual blood in subarachnoid cavity, reduce the level of destruction of the blood brain barrier, reduce the degree of cerebral basilar artery vasospasm and increase the nerve function score. Through the improvement of the above clinical indicators, the prognoses of patients are improved, and the therapeutic action on subarachnoid hemorrhage is remarkable.

Provided are a ceria nanocomposite including a ceria nanoparticle for treating subarachnoid hemorrhage, a method of preparing the same, and a pharmaceutical composition including the ceria nanocomposite. The ceria nanocomposite for treating subarachnoid hemorrhage disclosed herein includes a ceria nanoparticle and a surface modified layer disposed on a surface of the ceria nanoparticle, wherein the surface modified layer includes a polyethylene glycol residue.

This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury.

A method for attenuating vasoconstriction in a patient with subarachnoid hemorrhage by administering to the patient a therapeutically effective amount of a compound which mediates an increase of bioactive nitric oxide in blood or tissue in the subarachnoid space to cause vasodilation in cerebral, carotid and basilar arteries after the administration of the compound, and wherein the administration of the compound does not reduce mean arterial blood pressure by more than 10%.

The present invention relates to nitric oxide releasing compounds and their use in the prevention, amelioration and/or therapy of nitric oxide (NO) deficiency induced disturbances of the cerebral microcirculation. The NO deficiency induced disturbances of the cerebral microcirculation may be due to an intracranial hemorrhage or stroke and can cause cerebrovascular spasms (or cerebral vasospasms) (CVS) and/or malperfusion of brain parenchyma caused by blood vessel and blood flow dysregulation which, in turn, can cause secondary neurological deficiencies (DIND) and/or brain infarction. Particularly, the present invention relates to the prevention, amelioration and/or therapy of delayed cerebral vasospasm-associated disorders after survived subarachnoidal hemorrhage by applying a NO-donor, most preferably Molsidomine.